Significant improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept

被引：0
|
作者：
Singh, A.
McHugh, N.
Wajdula, J. S.
Paolozzi, L.
Zang, C.
机构：
[1] Global Hlth Outcomes Assessment, Collegeville, PA USA
[2] Royal Natl Hosp Rheumat Dis, Bath, Avon, England
[3] Clin Res & Dev, Collegeville, PA USA
[4] Clin Res & Dev, Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：602 / 602
页数：1
相关论文
共 50 条
  • [1] Assessment of patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept for up to 160 weeks.
    Dijkmans, Benjamin A. C.
    Sieper, Joachim
    van der Linden, Sjef
    Sibilia, Jean
    Mola, Emilio Martin
    Leirisalo-Repo, Marjatta
    Pedersen, Ronald
    Singh, Amitabh
    Freundlich, Bruce
    MacPeek, David
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S725 - S725
  • [2] Patient reported outcomes of improvement in patients with ankylosing spondylitis treated iwth etanercept for 148 to 160 weeks
    Dijkmans, B. A. C.
    Sieper, J.
    Van der Linden, S.
    Sibilia, J.
    Mola, E. Martin
    Leirisalo-Repo, M.
    Pedersen, R.
    Singh, A.
    Freundlich, B.
    MacPeek, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 432 - 432
  • [3] The effects of etanercept on patient-reported outcomes for subjects with ankylosing spondylitis.
    van der Heijde, D
    Dougados, M
    Davis, JC
    Woolley, JM
    Tsuji, W
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S174 - S175
  • [4] Improvements in patient-reported outcomes for subjects with ankylosing spondylitis receiving etanercept therapy
    Davis, JC
    Woolley, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 252 - 252
  • [5] Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
    Braun, J.
    McHugh, N.
    Singh, A.
    Wajdula, J. S.
    Sato, R.
    RHEUMATOLOGY, 2007, 46 (06) : 999 - 1004
  • [6] Assessment of patient-reported outcomes from a randomized, DoubleBlind study of etanercept and Sulphasalazine in patients with Ankylosing spondylitis
    Sieper, J.
    Moots, R.
    Taylor, A.
    Sato, R.
    Singh, A.
    Robertson, D.
    Freundlich, B.
    Koenig, A. S.
    Vlahos, B.
    Ganguly, R.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S580 - S581
  • [7] Five-year efficacy and safety, including patient-reported outcomes, with etanercept in ankylosing spondylitis
    Mola, E. Martin
    van der Linden, S.
    Wishneski, C.
    Robertson, D.
    Freundlich, B. F.
    Koenig, A. S.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S584 - S585
  • [8] Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
    Martin-Mola, E.
    Sieper, J.
    Leirisalo-Repo, M.
    Dijkmans, B. A. C.
    Vlahos, B.
    Pedersen, R.
    Koenig, A. S.
    Freundlich, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 238 - 245
  • [9] Long term efficacy and safety results and patient reported outcomes in patients with ankylosing spondylitis treated with etanercept for 4 years
    Dijkmans, B. A. C.
    Sieper, J.
    van der Linden, S.
    Martin-Mola, E.
    Leirisalo-Repo, M.
    Singh, A.
    Freundlich, B.
    Koenig, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 395 - 395
  • [10] Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
    Ogdie, Alexis
    Hwang, Mark
    Veeranki, Phani
    Portelli, Alexandria
    Sison, Steven
    Shafrin, Jason
    Pedro, Sofia
    Yi, Esther
    Michaud, Kaleb
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345